Author

V. S. Iyer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

F. Wermeling· 2 shared L. Jiang· 2 shared S. V. Boddul· 2 shared Y. Shen· 2 shared Z. Kasza· 2 shared B. Raposo· 1 shared D. P. Lane· 1 shared K. Ingelshed· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

9 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Wermeling

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 10, 2021

CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited.

L. Jiang, K. Ingelshed, Y. Shen…·F. Wermeling

The paper shows that CRISPR enriches cells with p53-related mutations and demonstrates that transient p53 inhibition can suppress this effect.

DOI 10.1101/2021.03.10.434760

humanCRISPR screen

𝕏 PostBluesky

ImmunologybioRxivMar 8, 2021

A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system

Y. Shen, L. Jiang, V. S. Iyer…·F. Wermeling

This paper introduces a CRISPR-based assay to identify drug targets affecting hematopoietic cells by analyzing genotype enrichment in mixed CRISPR populations.

DOI 10.1016/j.csbj.2021.09.020

humanexperimental assay

𝕏 PostBluesky